{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-028803","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.739527+00:00","generated_at":"2026-05-24T03:51:01.526011+00:00","sec_items":["3.01","5.02","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annovis Bio receives NYSE delisting notice, market cap ~$37.9M, equity $9.3M; CFO Fricker departs","bullets":["NYSE notice: 30-day avg mkt cap ~$37.9M, equity $9.3M at Dec 31, 2024, both below $50M thresholds.","Company has 45 days to submit compliance plan; NYSE may grant up to 18-month cure period; symbol gets '.BC' indicator.","No immediate impact on stock listing, business operations, or SEC reporting obligations.","Interim CFO William Fricker departs March 27 by mutual agreement; no dispute over accounting.","CEO Maria Maccecchini assumes interim principal financial officer role."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-028803","json":"https://secwatch.observer/filing/0001104659-25-028803.json","markdown":"https://secwatch.observer/filing/0001104659-25-028803.md","text":"https://secwatch.observer/filing/0001104659-25-028803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925028803/0001104659-25-028803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925028803/tm2510633d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:51:01.526011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05d7770209","claim":"William Fricker departed as Interim Chief Financial Officer at Annovis Bio, Inc..","evidence_excerpt":"On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925028803/0001104659-25-028803-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"90d8c5ab89","claim":"Maria Maccecchini was appointed as Principal Financial Officer on an interim basis at Annovis Bio, Inc..","evidence_excerpt":"Maria Maccecchini will continue to serve as principal financial officer on an interim basis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925028803/0001104659-25-028803-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer on an interim basis"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}